Abstracts tagged "positron emission tomography (PET) and synovitis"

Abstract Number: 2011 • 2017 ACR/ARHP Annual Meeting
Assessment of Methods to Quantitatively Evaluate Global Synovitis Activity with FDG-PET/CT
William Y. Raynor¹, Venkata S. Jonnakuti¹, Kaiyuan Zheng¹, Poul Flemming Høilund-Carlsen², Abass Alavi³ and Joshua Baker⁴, ¹Radiology, University of Pennsylvania, Philadelphia, PA, ²Nuclear Medicine, Odense University Hospital, Odense, Denmark, ³Department of Radiology/Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Fluorodeoxyglucose (FDG)-positron emission tomography (PET) allows more direct assessment of inflammation than other imaging modalities by portraying metabolic activity. No standards exist for objective…
Abstract Number: 1288 • 2016 ACR/ARHP Annual Meeting
Evaluating Rheumatoid Arthritis Disease Activity Using Global Assessment of 18f-FDG Uptake in the Joints
William Raynor¹, Sara Alehashemi², Sina Houshmand³, Thomas J Werner³, Abass Alavi⁴ and Joshua Baker⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Rheumatology, National Institutes of Health, Bethesda, MD, ³Radiology, University of Pennsylvania, Philadelphia, PA, ⁴Department of Radiology/Division of Nuclear Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Clinical imaging modalities in rheumatoid arthritis (RA) such as MRI and ultrasound can detect morphologic changes associated with synovial inflammation. 18F-labeled fluorodeoxyglucose positron emission…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].